Scinovex
article Open AccessTop 1% cited

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

The Lancet Oncology · 2012 · Vol. 13(3) · pp. 239–246
Rafael RosellEnric CarcerenyRadj GervaisA. VergnenègreBartomeu MassutíEnriqueta FelipRamón PalmeroRamón García-GómezCinta PallarésJosé Miguel SánchezRut PortaManuel CoboPilar GarridoFlavia LongoTeresa MoránAmelia InsaFilippo de MarinisR. CorreIsabel BoverAlfonso IllianoÉric DansinJavier de CastroMichèle MilellaNoemı́ ReguartGiuseppe AltavillaUlpiano JiménezMariano ProvencioMiguel Ángel MorenoJosefa TerrasaJosé Muñoz-LangaJavier ValdiviaDolores IslaManuel DómineOlivier MolinierJulien MazièresNathalie BaizeRosario García‐CampeloG. RobinetDelvys Rodríguez‐AbreuGuillermo López-VivancoVittorio GebbiaLioba Ferrera-DelgadoP. BombaronReyes BernabéAlessandra BearzÁ. ArtalEnrico CortesiChristian RolfoMaría Sanchez-RoncoAna DrozdowskyjCristina QueraltItziar de AguirreJosé Luis RamírezJosé Javier SánchezMiguel Ángel Molina‐VilaMiquel TarónLuis Paz‐Ares
Lung Cancer Treatments and MutationsLung Cancer Research StudiesColorectal Cancer Treatments and StudiesErlotinibMedicineDocetaxelInternal medicineOncologyCarboplatinGemcitabineLung cancerChemotherapyPopulation

MeSH terms

Erlotinib HydrochlorideDocetaxelGemcitabineAdministration, OralAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineDrug Administration ScheduleEuropeExonsFemaleHumansLung Neoplasms
Citations
5,500
FWCI
372.84
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.